The Paris Life Sciences team advised AlgoTx in its €20 million Series B.
AlgoTx develops novel solutions for complex pain. Their lead program, ATX01, targets highly prevalent Chemotherapy-Induced Peripheral Neuropathy and the orphan disease erythromelalgia.
This fundraising was led by Turenne Capital, followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Goodwin also advised historical investors.
The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
The Goodwin team was led by Anne-Charlotte Rivière and included Louis Taslé d’Héliand, Grégoire Mongis and Coralie Davis on corporate aspects.